TABLE 3.

Clinical trials that studied arabinoxylan consumption in adults without gastrointestinal disease¹

Study	Population	Design	Duration	Dose	Control (vehicle)	Treatment (vehicle)	Assessment	Responses
Scarpellini, 2018 (39)	Healthy adults in Belgium (n = 13; 7 F, 6 M), 18–42 y, BMI 21.6 ± 1.6	Single blind, crossover, placebo controlled	12 h prior to study and next morning for test	9.4 g/d	Maltodextrin (warm water)	Fugeia NV's Brana Vita 200 AXOS from wheat bran extract (warm water)	Transit time	Treatment did not affect transit time compared with control
Lu, 2004 (40)	Adults in Australia (n = 15; 9 F, 6 M) with T2D, 60 ± 2 y, BMI 28.1 ± 0.9	Randomized, crossover	Two 5-wk periods	15.1 g/d	50% whole wheat, 50% white flour (bread and muffins)	14% AX, 50% whole wheat, 36% white flour (bread and muffins)	Scored daily stool frequency from 1 (much less) to 9 (much greater than usual); side effects, fecal weight, 24-h fecal collection	Treatment ↑ stool frequency (P < 0.05) and wet weight (P = 0.05) compared with control.2 No differences in flatulence, distension, or cramping between treatment and control

¹BMI is presented as kg/m². AX, arabinoxylan; AXOS, arabinoxylooligosaccharide; T2D, type 2 diabetes.

²Differences were statistically significant (P ≤ 0.05).